At least four isoforms of DPAGT1 are known to exist, this antibody will recognize the two longest isoforms. DPAGT1 antibody is predicted to not cross-react with UHRF1BP1.
Purification
DPAGT1 Antibody is affinity chromatography purified via peptide column.
Immunogen
DPAGT1 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human DPAGT1. The immunogen is located within amino acids 30 - 80 of DPAGT1.
DPAGT1
Reactivity: Mouse, Rat
WB, IF (cc), IF (p)
Host: Rabbit
Polyclonal
Alexa Fluor 555
Application Notes
DPAGT1 antibody can be used for detection of DPAGT1 by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in mouse samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
DPAGT1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
DPAGT1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
DPAGT1 Antibody: The UDP-N-acetylglucosamine-dolichyl-phosphate N-acetyl-glucosaminephosphotransferase (DPAGT1) is an enzyme that catalyzes the first step in the dolichol-linked oligosaccharide pathway for glycoprotein biosynthesis. Mutations in this integral endoplasmic reticulum (ER) membrane protein enzyme belongs to the glycosyltransferase family 4 results in the congenital disorder of glycosylation type Ij with symptoms such as severe hypotonia, medically intractable seizures, mental retardation, microcephaly, and exotropia. Recent experiments have shown that DPAGT1 is a target of the Wnt/beta-catenin signaling pathway, with Wnt3a inducing higher DPAGT1 mRNA expression.